Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TREPROSTINIL Cause Product dose omission issue? 1,672 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,672 reports of Product dose omission issue have been filed in association with TREPROSTINIL (TYVASO). This represents 1.8% of all adverse event reports for TREPROSTINIL.

1,672
Reports of Product dose omission issue with TREPROSTINIL
1.8%
of all TREPROSTINIL reports
41
Deaths
451
Hospitalizations

How Dangerous Is Product dose omission issue From TREPROSTINIL?

Of the 1,672 reports, 41 (2.5%) resulted in death, 451 (27.0%) required hospitalization, and 18 (1.1%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 1,672 reports have been filed with the FAERS database.

What Other Side Effects Does TREPROSTINIL Cause?

Dyspnoea (16,348) Headache (14,051) Diarrhoea (11,335) Nausea (10,320) Cough (8,945) Fatigue (7,440) Dizziness (7,405) Infusion site pain (5,169) Vomiting (5,097) Death (4,764)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which TREPROSTINIL Alternatives Have Lower Product dose omission issue Risk?

TREPROSTINIL vs TREPROSTINIL DIOLAMINE TREPROSTINIL vs TRETINOIN TREPROSTINIL vs TRIAMCINOLONE TREPROSTINIL vs TRIAMCINOLONE ACETONIDE TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE

Related Pages

TREPROSTINIL Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue TREPROSTINIL Demographics